Showing 1 - 4 results of 4 for search 'Frank Behrens', query time: 0.01s Refine Results
  1. 1
    Uveitis in patients with axial spondyloarthritis or psoriatic arthritis: a post hoc analysis from placebo-controlled phase III studies with secukinumab

    Uveitis in patients with axial spondyloarthritis or psoriatic arthritis: a post hoc analysis from placebo-controlled phase III studies with secukinumab by Jan Brandt-Jürgens, Martin Rudwaleit, Frank Behrens, Christopher Ritchlin, Daniel Peterlik, Erhard Quebe-Fehling, Atul Deodhar

    Published 2025-06-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors

    Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and pr... by Peter Nash, Frank Behrens, Ana-Maria Orbai, Suchitrita S Rathmann, David H Adams, Olivier Benichou, Atul Deodhar

    Published 2018-09-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Proteomic, metabolomic and lipidomic profiles in community acquired pneumonia for differentiating viral and bacterial infections

    Proteomic, metabolomic and lipidomic profiles in community acquired pneumonia for differentiating viral and bacterial infections by Samuel Rischke, Robert Gurke, Ann-Sophie Zielbauer, Nicole Ziegler, Lisa Hahnefeld, Michaela Köhm, Aimo Kannt, Maria JGT Vehreschild, Gerd Geisslinger, Gernot Rohde, Carla Bellinghausen, Frank Behrens, CAPNETZ Study group

    Published 2025-01-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL

    Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III... by Robert Landewé, Joseph F Merola, Laure Gossec, Frank Behrens, Ana-Maria Orbai, Philip J Mease, Iain B McInnes, Yoshiya Tanaka, Dafna D Gladman, Laura C Coates, Alice B Gottlieb, Vishvesh Shende, Jason Coarse, Christopher T Ritchlin, Richard B Warren, Akihiko Asahina, Barbara Ink, Rajan Bajracharya

    Published 2024-02-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: